Recent studies have shown that non-invasive approaches based on PET/CT, for example, analysis of 18F-FDG uptake (SUVmax, metabolic volume, tumor lesion glucose) and 18F-FDG PET/CT-derived radiomics (46, 47) could help quantify EGFR mutation status and predict prognosis in lung cancer patients for precision therapy. This evidence concerns the gene EGFR and lung carcinoma.